Kala Pharmaceuticals, Inc. (KALA) Reaches $17.24 After 8.00% Down Move; Capital Planning Advisors Has Upped By $942,700 Its Dover (DOV) Position

April 10, 2018 - By Adrian Mccoy

Dover Corporation (NYSE:DOV) Logo

The stock of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is a huge mover today! The stock decreased 1.43% or $0.25 during the last trading session, reaching $17.24. About 60,653 shares traded. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has 0.00% since April 10, 2017 and is . It has underperformed by 11.55% the S&P500.The move comes after 7 months negative chart setup for the $423.35 million company. It was reported on Apr, 10 by Barchart.com. We have $15.86 PT which if reached, will make NASDAQ:KALA worth $33.87M less.

Capital Planning Advisors Llc increased Dover Corp (DOV) stake by 56.96% reported in 2017Q4 SEC filing. Capital Planning Advisors Llc acquired 9,427 shares as Dover Corp (DOV)’s stock declined 2.34%. The Capital Planning Advisors Llc holds 25,977 shares with $2.62M value, up from 16,550 last quarter. Dover Corp now has $14.57 billion valuation. The stock increased 1.38% or $1.28 during the last trading session, reaching $94.28. About 441,489 shares traded. Dover Corporation (NYSE:DOV) has risen 25.93% since April 10, 2017 and is uptrending. It has outperformed by 14.38% the S&P500.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle Mucus Penetrating Particles technology. The company has market cap of $423.35 million. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It currently has negative earnings. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases.

Since October 23, 2017, it had 1 insider purchase, and 8 sales for $7.26 million activity. The insider Burns Patrick bought $61,908. Goldberg Paul also sold $336,600 worth of Dover Corporation (NYSE:DOV) shares. $511,965 worth of Dover Corporation (NYSE:DOV) was sold by Somasundaram Sivasankaran on Friday, March 9. The insider STUBBS MICHAEL B sold 8,495 shares worth $818,048. Kosinski Anthony K also sold $549,708 worth of Dover Corporation (NYSE:DOV) on Friday, March 9. Spurgeon William sold $624,203 worth of Dover Corporation (NYSE:DOV) on Thursday, October 26.

Among 23 analysts covering Dover (NYSE:DOV), 12 have Buy rating, 0 Sell and 11 Hold. Therefore 52% are positive. Dover had 97 analyst reports since July 22, 2015 according to SRatingsIntel. As per Friday, August 25, the company rating was maintained by BMO Capital Markets. The stock has “Hold” rating by Stifel Nicolaus on Thursday, October 20. Robert W. Baird maintained Dover Corporation (NYSE:DOV) rating on Thursday, August 24. Robert W. Baird has “Buy” rating and $91.0 target. Seaport Global maintained it with “Hold” rating and $110.0 target in Thursday, February 1 report. The stock of Dover Corporation (NYSE:DOV) has “Outperform” rating given on Monday, March 14 by Credit Suisse. RBC Capital Markets maintained it with “Hold” rating and $9100 target in Thursday, July 20 report. Stifel Nicolaus maintained the stock with “Hold” rating in Tuesday, December 13 report. Stifel Nicolaus maintained it with “Hold” rating and $100.0 target in Sunday, December 10 report. On Tuesday, January 30 the stock rating was maintained by RBC Capital Markets with “Hold”. On Tuesday, April 19 the stock rating was maintained by Citigroup with “Neutral”.

Dover Corporation (NYSE:DOV) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>